Site updated at Wednesday, 22 June 2016

Living with Dementia


Eli Lilly Announces FDA Approval of Amyvid For Alzheimer’s Assessment

Eli Lilly and Company (NYSE: LLY) and Avid Radiopharmaceuticals, Inc., a wholly owned subsidiary of Lilly, today announced the U.S. Food and Drug Administration (FDA) approval of Amyvid™, a radioactive diagnostic agent indicated for brain imaging of beta-amyloid plaques in patients with cognitive impairment who are being evaluated for Alzheimer’s Disease and other causes… Eli Lilly Announces FDA Approval of Amyvid For Alzheimer’s Assessment   

FDA OKs Agent to Differentiate Alzheimer’s

The FDA has approved the radioactive diagnostic agent florbetapir (Amyvid) for evaluation of the causes of cognitive decline, including Alzheimer’s disease, according to Eli Lilly, developer of the compound.

Florbetapir is used in conjunction with positron emission tomography to evaluate the burden of amyloid plaques in the brain, according to Daniel Skovronsky, MD, PhD,… FDA OKs Agent to Differentiate Alzheimer’s   


exercise2 - mixed forms1 - alzheimer's markers1 - cardiac arrest1 - donepezil3 - presenile-onset disease1 - alzheimers association1 - medical history1 - depressive pseudodementia1 - fragmentation of dementia1 - amyloid-beta peptides1 - high blood pressure7 - amyloid beta peptide1 - rheumatoid arthritis1 - dementia135 - social withdrawal1 - vision1 - risk of stroke1 - dopamine levels1 - cause of dementia5 - pet1 - symptoms of parkinson's3 - knopman1 - signs of dementia6 - omega-31 - the gerontologist1 - wernicke disease1 - clinical observations1 - idiocy1 - early alzheimer's damage1 -